stockrowKiniksa Pharmaceuticals International, plc
KNSA Healthcare Drug Manufacturers Specialty & Generic
Kiniksa Pharmaceuticals International, plc’s revenue for fiscal 2025 (year ended December 2025) was $677.6 million, up 60.1% from fiscal 2024.
- Revenue
- +58.1%
- EPS
- +142.2%
- Free cash flow
- +43.5%
Quarter to September 2026, against a year earlier
Follow KNSA
Alert me
Kiniksa Pharmaceuticals International, plc (KNSA) Free cash flow
Kiniksa Pharmaceuticals International, plc's free cash flow for fiscal 2025 was $136.4M, up 436.3% from $25.4M in fiscal 2024. Over the twelve months to 30 September 2026 it was $197.2M. Over the past ten years it has ranged from −$161.6M (fiscal 2019) to $136.4M (fiscal 2025) — the current reading is the highest in ten years. Free cash flow has risen for 4 consecutive fiscal years. Kiniksa Pharmaceuticals International, plc ranks 17th of 84 Drug Manufacturers Specialty & Generic companies by free cash flow.
Free cash flow, annual
Embed this chart
Annual newest first
| Period | Free cash flow | Change |
|---|---|---|
| FY2025 | $136.4M | 436.29% |
| FY2024 | $25.4M | 93.13% |
| FY2023 | $13.2M | 127.36% |
| FY2022 | $5.8M | — |
| FY2021 | −$146.7M | — |
| FY2020 | −$136.8M | — |
| FY2019 | −$161.6M | — |
| FY2018 | −$86.3M | — |
| FY2017 | −$50.3M | — |
| FY2016 | −$21.9M | — |
Quarterly newest first
| Period | Free cash flow | Change |
|---|---|---|
| Sep 2026 | $47.4M | 1.79% |
| Jun 2026 | $46.5M | (7.01%) |
| Mar 2026 | $50.0M | (6.05%) |
| Dec 2025 | $53.3M | 61.37% |
| 35 more quarters | Free account |
Against its own ten years
Free cash flow against peers
| Company | Free cash flow |
|---|---|
| LNTH Lantheus Holdings, Inc. compare | $409.5M |
| ELAN Elanco Animal Health Incorporated compare | $379.0M |
| ALKS Alkermes plc compare | $228.4M |
| KNSA Kiniksa Pharmaceuticals International, plc | $197.2M |
| LQDA Liquidia Corporation compare | $150.7M |
| RDY Dr. Reddy's Laboratories Ltd compare | $96.0M |
| HIMS Hims & Hers Health, Inc. compare | $83.0M |
| SUPN Indivior Pharmaceuticals Inc. compare | $31.0M |
| AMRX AMNEAL PHARMACEUTICALS, INC. compare | −$60.5M |
What Free cash flow is
Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.
Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)
More on KNSA
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement